TuHURA Biosciences, Inc. - HURA

SEC Filings Our HURA Tweets

About Gravity Analytica

Recent News

11.04.2026 - TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
10.26.2026 - TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
10.13.2026 - TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
10.05.2026 - TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
09.14.2026 - TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
09.08.2026 - TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
08.14.2026 - TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
07.22.2026 - TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
06.15.2026 - TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
05.15.2026 - TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Recent Filings